Galera Therapeutics (NASDAQ:GRTX) Coverage Initiated by Analysts at Credit Suisse Group
Credit Suisse Group assumed coverage on shares of Galera Therapeutics (NASDAQ:GRTX) in a report issued on Monday, Benzinga reports. The firm issued a neutral rating and a $14.00 price target on the stock.
Other equities research analysts also recently issued research reports about the company. Bank of America started coverage on Galera Therapeutics in a report on Monday. They set a buy rating and a $15.00 price target on the stock. Citigroup started coverage on Galera Therapeutics in a report on Monday. They set a buy rating and a $20.00 price target on the stock.
Shares of NASDAQ GRTX opened at $12.07 on Monday. Galera Therapeutics has a 1-year low of $11.50 and a 1-year high of $14.88.
About Galera Therapeutics
Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.
Featured Article: How does a reverse stock split work?
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.